Vaccine News and Research

Latest Vaccine News and Research

Champions Biotechnology reports higher year-on-year operating revenues for fiscal year 2009

Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, today announced its financial results for the fiscal year ended April 30, 2009. Full details of the Company's financial results are available in the Company's Form 10-K available at www.championsbiotechnology.com.

28 Aug 2009

Chk1 and Fbx6 play an important role for the regulation of response to chemotherapy

Cell cycle checkpoints act like molecular tripwires for damaged cells, forcing them to pause and take stock. Leave the tripwire in place for too long, though, and cancer cells will press on regardless, making them resistant to the lethal effects of certain types of chemotherapy, according to researchers at the Salk Institute for Biological Studies.

28 Aug 2009

Brazil emerges as country with highest number of H1N1-related deaths

The H1N1 (swine) flu is blamed for 557 deaths in Brazil, "making it the country with the highest number of fatalities in the world from the disease," according to the country's health ministry, Agence France-Presse reports. "Brazil's health ministry said in a statement the government was freeing up one billion dollars to buy 73 million doses of a new vaccine being developed against swine flu, as well as Tamiflu stocks, hospital equipment and diagnostic gear," the news service writes (8/26).

28 Aug 2009

Majority of Americans are ready to get vaccinated against H1N1 flu virus

A recent poll on the H1N1 flu conducted by the American Red Cross found that more Americans are taking or planning on taking extra measures to cover their coughs and sneezes with tissue (78%) or wash their hands more carefully (76%) to avoid getting the flu.

27 Aug 2009

Geron provides additional comments on the recent clinical hold of Spinal Cord Injury IND

Geron Corporation today provided additional comments on the recent clinical hold on its Spinal Cord Injury IND.

27 Aug 2009

EDCTP welcomes proposals for tuberculosis vaccines and HIV/AIDS treatment projects

EDCTP welcomes project proposals as a response to the following calls: Tuberculosis vaccines, HIV/AIDS treatment and Member States Initiated projects.

27 Aug 2009

BMSN and ENTB collaborate with Therinjectto to develop a new immuno-therapeutic cancer vaccine

Bio-Matrix Scientific Group, Inc. and Its majority owned subsidiary Entest BioMedical Inc. announced today they have finalized a definitive agreement with Therinject LLC for the development of a new immuno-therapeutic cancer vaccine. Therinject LLC is engaged in the development of cancer treatments utilizing immunology based approaches.

27 Aug 2009

Lakewood-Amedex to speed up development of its broad spectrum anti-influenza product into clinical studies

Lakewood-Amedex Inc., (L-A), the anti-infectives biopharmaceutical company developing a unique portfolio of anti-bacterial and anti-viral products including NuBiotics, a novel family of synthetic anti-bacterial compounds, and anti-viral products against hepatitis, HIV and influenza, announced today that it is accelerating development of its broad spectrum anti-influenza product into clinical studies.

27 Aug 2009

FDA releases consumer health information updates

The U.S. Food and Drug Administration today released its latest listing of consumer health information updates. All articles can be accessed from the agency's Web page for consumers. You can sign-up for e-mail notices of new consumer updates on an immediate, weekly, or monthly basis. A Consumer Update RSS feed is also available.

27 Aug 2009

Asia will experience H1N1 vaccine shortage, WHO says

A spokesperson for the WHO said on Tuesday that Asia will not have enough H1N1 vaccines for swine flu when cold weather hits, Reuters reports.

26 Aug 2009

Important development in the treatment of multiple sclerosis

A major step forward, with important implications for understanding how to reduce the severity of multiple sclerosis, has been made by scientists at the University of Bristol. The results are published online today in PNAS.

26 Aug 2009

Lack of imagination and aversion to commercial risk are the biggest threats to Australia’s medical innovation

Australia could be a world leader in medical innovation but commercial risk aversion and parochialism are holding the industry back, a leading venture capitalist will argue at a public lecture and debate at the University of New South Wales next week (Monday, 31 August).

26 Aug 2009

DAS181 inhibits H5N1 Influenza lung virus infection of human lung tissues

NexBio, Inc. announced today the publication "DAS181 Inhibits H5N1 Influenza Lung Virus Infection of Human Lung Tissues" in the September, 2009 issue of the journal Antimicrobial Agents and Chemotherapy (AAC).

26 Aug 2009

Public and private sector players ready to tackle North America’s upcoming flu season

An MIT Sloan School of Management expert on U.S. vaccine markets is “cautiously hopeful” that public and private sector players are far better prepared for North America’s upcoming flu season than they have been for earlier flu pandemics.

26 Aug 2009

Report warns H1N1 could affect half of U.S. population

A U.S. presidential panel report released Monday estimates H1N1 (swine) flu could infect up to half of the country's population, the Washington Post reports.

26 Aug 2009

Antimicrobial-resistant typhoid fever in U.S. patients is associated with international travel

Infection with an antimicrobial-resistant strain of typhoid fever among patients in the United States is associated with international travel, especially to the Indian subcontinent (India, Pakistan, and Bangladesh), according to a study in the August 26 issue of JAMA. The study also shows an increase in certain strains of typhoid fever that are resistant to the most commonly used medications for treatment.

26 Aug 2009

Washington Post examines development of vaccine for food borne intestinal illness

The Partnership for Public Service/Washington Post examines how decades of work by Navy scientist Patricia Guerry could lead to "the first vaccine for a food borne intestinal illness that affects hundreds of millions of people worldwide each year."

26 Aug 2009

Profectus BioSciences to conduct proof-of-concept studies with its rVSV vector technology

Profectus BioSciences, Inc. (Profectus), a clinical stage biopharmaceutical company focused on the development of novel vaccine candidates for serious chronic infections, announced today it has entered into a research collaboration agreement with the PATH Malaria Vaccine Initiative (MVI) to conduct proof-of-concept studies with its proprietary, recombinant vesicular stomatitis virus (rVSV) vector technology as a preventative malaria vaccine.

26 Aug 2009

Hiberix receives accelerated approval from FDA to overcome nationwide shortage

The U.S. Food and Drug Administration today approved Hiberix, a Haemophilus influenzae Type b (Hib) vaccine, as a booster dose for children 15 months through 4 years old. Hiberix is manufactured by GlaxoSmithKline, with U.S. headquarters in Research Triangle Park, N.C. and Philadelphia.

26 Aug 2009

Genvec to use $2.5 million grant from NIAID for the development of novel cell lines

GenVec, Inc. (Nasdaq: GNVC) announced today that it has received a Phase 2 Small Business Innovation and Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to support the development of GenVec's vector production technology.

25 Aug 2009

Vaccine News and Research

Latest Vaccine News and Research

Champions Biotechnology reports higher year-on-year operating revenues for fiscal year 2009

Chk1 and Fbx6 play an important role for the regulation of response to chemotherapy

Brazil emerges as country with highest number of H1N1-related deaths

Majority of Americans are ready to get vaccinated against H1N1 flu virus

Geron provides additional comments on the recent clinical hold of Spinal Cord Injury IND

EDCTP welcomes proposals for tuberculosis vaccines and HIV/AIDS treatment projects

BMSN and ENTB collaborate with Therinjectto to develop a new immuno-therapeutic cancer vaccine

Lakewood-Amedex to speed up development of its broad spectrum anti-influenza product into clinical studies

FDA releases consumer health information updates

Asia will experience H1N1 vaccine shortage, WHO says

Important development in the treatment of multiple sclerosis

Lack of imagination and aversion to commercial risk are the biggest threats to Australia’s medical innovation

DAS181 inhibits H5N1 Influenza lung virus infection of human lung tissues

Public and private sector players ready to tackle North America’s upcoming flu season

Report warns H1N1 could affect half of U.S. population

Antimicrobial-resistant typhoid fever in U.S. patients is associated with international travel

Washington Post examines development of vaccine for food borne intestinal illness

Profectus BioSciences to conduct proof-of-concept studies with its rVSV vector technology

Hiberix receives accelerated approval from FDA to overcome nationwide shortage

Genvec to use $2.5 million grant from NIAID for the development of novel cell lines

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Vaccine News and Research

Latest Vaccine News and Research

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Newsletters you may be interested in